Inmune Bio, INC Form 4 insider transactions

Inmune Bio Director Scott Juda exercised 14,801 warrants and secured an extension on the remaining warrants through a new agreement.

Inmune Bio's Chief Scientific Officer, Mark William Lowdell, exercised warrants for 7,211 shares of common stock and secured an extension on remaining warrants.

Inmune Bio CEO David J. Moss exercised 9,014 common stock purchase warrants and secured an extension for the remaining warrants.

Inmune Bio's Chief Scientific Officer, Mark William Lowdell, was granted 600,000 stock options with an exercise price of $1.48.

Inmune Bio, Inc. CEO David J. Moss received a grant of 750,000 stock options with a $1.48 exercise price, vesting over four years.

Inmune Bio's CFO, Cory Randall Ellspermann, was granted 300,000 stock options with an exercise price of $1.48, vesting over four years.

Inmune Bio, Inc. Director Timothy J. Schroeder was granted 150,000 stock options with an exercise price of $1.48, vesting over three years.

Inmune Bio, Inc. Director Scott Juda was granted 150,000 stock options with an exercise price of $1.48, vesting monthly over three years.

Inmune Bio, Inc. Director James Kelly Ganjei was granted 150,000 stock options with an exercise price of $1.48, vesting over three years.

Inmune Bio, Inc. Director Marcia Allen was granted 150,000 stock options with an exercise price of $1.48, vesting monthly over three years.

Inmune Bio, Inc. has repriced 366,000 stock options for Director Timothy J Schroeder to an exercise price of $1.50 per share, matching the closing stock price on November 18, 2025.

Inmune Bio, Inc. announced the repricing of CEO David Moss's stock options to $1.50 per share, aligning with the current market price.

Inmune Bio, Inc. repriced Chief Scientific Officer Mark William Lowdell's stock options to an exercise price of $1.50 per share.

Inmune Bio, Inc. director Scott Juda's stock options were repriced to $1.50 per share following stockholder approval.

Inmune Bio, Inc. announced a one-time repricing of certain outstanding stock options for Director James Kelly Ganjei, reducing the exercise price to $1.50 per share.

Inmune Bio's Interim CFO, Cory Randall Ellspermann, had 245,000 stock options repriced to an exercise price of $1.50 per share following stockholder approval.

Inmune Bio, Inc. has repriced certain outstanding stock options for Director Marcia Allen to an exercise price of $1.50 per share, reflecting the stock's closing price on November 18, 2025.

Inmune Bio's Chief Financial Officer, David Moss, was granted 223,000 stock options on December 5, 2024, which will vest in two years.

Inmune Bio's Chief Scientific Officer, Mark William Lowdell, was granted 140,000 stock options on December 5, 2024, which will vest in two years.

Marcia Allen, a director at Inmune Bio, Inc., was granted 32,500 stock options on December 5, 2024, which will vest in two years.

Inmune Bio director Scott Juda was granted 32,500 stock options on December 5, 2024, which will vest in two years.

Director Timothy Schroeder of Inmune Bio, Inc. was granted 32,500 stock options on December 5, 2024, which will vest in two years.

Inmune Bio's CEO, Raymond Tesi, was granted 226,000 stock options under the company's 2021 Stock Incentive Plan.

Director James Kelly Ganjei of Inmune Bio, Inc. was granted 32,500 stock options on December 5, 2024, which will vest on December 5, 2026.

David Moss, CFO of Inmune Bio, Inc., acquired 10,000 shares of common stock at $5.2868 per share on September 30, 2024, increasing his direct holdings to 1,285,869 shares.

Raymond Joseph Tesi, CEO of Inmune Bio, Inc., reports acquisition of common stock and warrants through a registered direct offering.

David Moss, CFO of Inmune Bio, Inc., reports the acquisition of common stock and warrants through a registered direct offering.

Director Scott Juda of Inmune Bio, Inc. [INMB] recently purchased 5,000 shares of common stock at $7.27 per share, increasing his indirect holdings.

Raymond Joseph Tesi, CEO of Inmune Bio, Inc., reports the acquisition of options to purchase 37,882 shares of common stock.

Raymond Joseph Tesi, CEO of Inmune Bio, Inc., reports the acquisition of 160,000 stock options on May 14, 2024.